Evidence map›Paper›PMID 35880498›Full record

ArticleBlood research2022

Relevance of flow cytometric categorization and end-of-induction measurable residual disease assessment in pediatric and adult T-lymphoblastic leukemia patients.

Karthik Bommannan, Jhansi Rani Arumugam, Venkatraman Radhakrishnan, Jayachandran Perumal Kalaiyarasi, Parathan Karunakaran, Nikita Mehra, Tenali Gnana Sagar, Shirley Sundersingh

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Karthik BommannanDepartments of Oncopathology, Cancer Institute (W.I.A.), Adyar, India.
Jhansi Rani ArumugamDepartments of Oncopathology, Cancer Institute (W.I.A.), Adyar, India.
Venkatraman RadhakrishnanDepartments of Medical Oncology, Cancer Institute (W.I.A.), Adyar, India.
Jayachandran Perumal KalaiyarasiDepartments of Medical Oncology, Cancer Institute (W.I.A.), Adyar, India.
Parathan KarunakaranDepartments of Medical Oncology, Cancer Institute (W.I.A.), Adyar, India.
Nikita MehraDepartments of Medical Oncology, Cancer Institute (W.I.A.), Adyar, India.
Tenali Gnana SagarDepartments of Medical Oncology, Cancer Institute (W.I.A.), Adyar, India.
Shirley SundersinghDepartments of Oncopathology, Cancer Institute (W.I.A.), Adyar, India.
Cancer Institute (WIA) · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: T-lymphoblastic leukemia (T-ALL) patients expressing myeloid/stem cell antigens are classified as early T-cell precursor lymphoblastic leukemia (ETP-ALL) or near-ETP-ALL. Methods: Clinico-laboratory profiles, flow cytometric end-of-induction measurable residual disease (EOI-MRD), and survival of treatment naïve T-ALL patients were analyzed according to their immunophenotypic subtypes. Results: Among 81 consecutive T-ALL patients diagnosed, 21% (N=17) were ETP-ALL and 19% (N=15) were near-ETP-ALL. EOI-MRD was detectable in 39% of the 59 samples tested (31.6% of pediatric samples and 52.4% of adult samples). The frequency of EOI-MRD positivity was significantly higher among ETP-ALL (75%, Conclusion: Two-year survival among pediatric and adult T-ALL patients is attributed to EOI-MRD status and near-ETP-ALL phenotype, respectively.

Indexed as

ETP-ALLFlow cytometryMeasurable residual diseaseNear-ETP-ALLT-lineage acute lymphoblastic leuke mia

Identifiers

PMID35880498
PMCPMC9492521
OpenAlexW4287958230

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.